EP4223292A1 — Pharmaceutical combinations for treating cancer
Assigned to Cellestia Biotech AG · Expires 2023-08-09 · 3y expired
What this patent protects
The present invention relates to pharmaceutical combinations comprising a taxane and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
USPTO Abstract
The present invention relates to pharmaceutical combinations comprising a taxane and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.